Related Experiment Video

Updated: Jun 26, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

Charles Dumontet1, Mary Ann Jordan, Francis F Y Lee

  • 1Unité Institut National de la Sante et de la Recherche Medicale 590, Laboratoire de Cytologie Analytique, Faculté de Médecine Rockefeller, 8 Avenue Rockefeller, 69373 Lyon Cedex 08, France. charles.dumontet@chu-lyon.fr

Molecular Cancer Therapeutics
|January 14, 2009
PubMed

Insights

Chemotherapy resistance in cancer can be overcome by targeting betaIII-tubulin. Ixabepilone shows promise in treating taxane-resistant tumors by suppressing microtubule dynamics in cells with high betaIII-tubulin expression.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Microtubule-targeting agents like taxanes are crucial in cancer chemotherapy.
  • Chemotherapy resistance, particularly to taxanes, is a major clinical challenge.
  • Overexpression of betaIII-tubulin is a known mechanism of taxane resistance.

Purpose of the Study:

  • To investigate the role of betaIII-tubulin in taxane resistance.
  • To evaluate the efficacy of ixabepilone, an epothilone B analogue, in overcoming taxane resistance.
  • To explore the mechanism by which ixabepilone exerts its antitumor activity.

Main Methods:

  • Analysis of beta-tubulin isotype expression in tumors.
  • Clinical studies evaluating ixabepilone in patients with resistant cancers.
  • Assessment of ixabepilone's effect on microtubule dynamics in cells with varying betaIII-tubulin levels.

Main Results:

  • BetaIII-tubulin overexpression correlates with poor clinical outcomes in several cancers.
  • Ixabepilone demonstrates significant antitumor activity in taxane-resistant tumors.
  • Ixabepilone preferentially suppresses the dynamic instability of alpha/betaIII-microtubules.

Conclusions:

  • Targeting betaIII-tubulin offers a strategy to overcome taxane resistance.
  • Ixabepilone is an effective therapeutic option for patients with taxane-resistant malignancies.
  • The mechanism of ixabepilone involves specific disruption of microtubule dynamics in betaIII-tubulin-expressing cells.

More Related Videos

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...